OncoCyte Corp (NYSE American:OCX)
| 1.79 BATS BZX Real-Time Price As of 10:37am ET |  +0.01 / +0.56%Today’s Change | 1.20 Today|||52-Week Range 3.51 | -20.44% Year-to-Date |
Latest OCX News | Press Releases
| Oncocyte Corporation's (OCX) CEO Ronnie Andrews on Q2 2020 Results - Earnings Call Transcript Jul 29 / Seeking Alpha - Paid Partner Content | OncoCyte EPS misses by $0.04, beats on revenue Jul 29 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 1.78 |
| Today’s open | 1.79 |
| Day’s range | 1.77 - 1.80 |
| Volume | 104,030 |
| Average volume (3 months) | 786,249 |
| Market cap | $91.5M |
Data as of 10:35am ET, 08/06/2020
Growth & Valuation
| Earnings growth (last year) | -5.05% |
| Earnings growth (this year) | -2.27% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 2.50 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CEMIChembio Diagnostics ... | -0.40 | -6.77% |
| BLPHBellerophon Therapeu... | -0.59 | -4.66% |
| AXGTAxovant Gene Therapi... | 0.00 | 0.00% |
| NBRVNabriva Therapeutics... | -0.01 | -0.73% |
Data as of 10:39am ET, 08/06/2020
Financials
| Next reporting date | November 11, 2020 |
| EPS forecast (this quarter) | -$0.10 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$22.4M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Irvine, California |
Forecasts
